Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia.

Thrombospondin-1 (TSP1) is a Mr 450,000 extracellular matrix glycoprotein that modulates tumor growth, angiogenesis, and metastasis. Of the five structurally different TSPs described to date, only TSP2 is similar to TSP1 in terms of its molecular architecture, and TSP2 also modulates angiogenesis. Angiogenesis plays a relevant role in the biological aggressiveness of breast cancer, and TSP1 is present in the tumor stroma (termed desmoplasia) of invasive human breast ductal carcinoma not otherwise specified (NOS). The present study was designed to identify and quantify TSP1 and TSP2 mRNAs in normal, benign, and neoplastic human breast tissues using the reverse transcriptase PCR technique. We found that TSP2, like TSP1, was expressed in human breast tissues, and that TSP1 and TSP2 mRNA expression in invasive breast carcinoma NOS was significantly increased compared to that observed in normal and benign tissues. The expression of TSP1 and TSP2 in invasive breast ductal carcinoma NOS did not significantly correlate with any of the prognostic factors studied (tumor size, lymph node status, morphology, and hormone receptor status). However, when our study population was divided according to the quantity of tumor stroma, TSP1 (and possibly TSP2) mRNA expression and microvessel counts in desmoplastic-rich stroma of breast carcinoma NOS were significantly increased compared to those observed in desmoplastic-poor stromata.

[1]  G. Tuszynski,et al.  Matrix-bound thrombospondin promotes angiogenesis in vitro , 1994, The Journal of cell biology.

[2]  P. Delmas,et al.  Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast. , 1993, Cancer research.

[3]  A. Harris,et al.  Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  O. Volpert,et al.  Inhibition of angiogenesis by thrombospondin-2. , 1995, Biochemical and biophysical research communications.

[5]  P. Steeg,et al.  Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. , 1994, Cancer research.

[6]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[7]  W. Miller,et al.  Thrombospondin in malignant and non-malignant breast tissue. , 1989, European journal of cancer & clinical oncology.

[8]  S. Wong,et al.  Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study. , 1992, The American journal of pathology.

[9]  D. Roberts,et al.  Regulation of tumor growth and metastasis by thrombospondin‐1 , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  G. Tuszynski,et al.  The role of thrombospondin-1 in tumor progression and angiogenesis. , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.